Hydroxychloroquine in the treatment of the lupus nephritis

Whether can hydroxychloroquine accentuatein renal tubular damage treatmenting with lupus nephritis patients of proteinuria

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-13004257

Enrollment

Unknown

Registered

2013-11-28

Start date

2014-01-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Systemiclupuserythematosus Lupusnephritis

Interventions

treatment group:Basal immunotherapy and hydroxychloroquine

control group:Basal immunotherapy

Eligibility

Sex/Gender

All

Age

15 Years to 60 Years

Inclusion criteria

Inclusion criteria: (1) the incipient lupus patients or stop immunosuppressive therapy for more than six months and the recurrence of lupus patients; (2) aged 18 to 60 years old; (3) the classification of systemic lupus erythematosus (sle) patients with diagnostic criteria (ACR) into the group; (4) with lupus nephritis in pathological type VI, V or V + III/IV; (5) the urinary protein more than 2.0 g/d. (6) signed a written informed consent.

Exclusion criteria

Exclusion criteria: (1) patients with severe infection (except those have been largely control before attending); (2) patients in lung, lupus erythematosus mental nerve disease and other lupus crisis may endanger the life of the patients; (3) the clinical manifestations of the accelerated glomerular nephritis, or pathological diagnosis for the crescent shape glomerulonephritis, or kidney CI index (chronic) score is greater than 6 points; (4) the patients should not use "prednisone + CTX" as the basic immunosuppressive therapy, or need to add in other immunosuppressants; (5) patients with hydroxychloroquine allergies or lack of G6 - PD, mergering fundus diseases, sclera diseases or vitreous disease such as unfavorable application hydroxychloroquine patients; (6) with severe gastrointestinal tract complications or other reasons patients can't accept oral drug treatment; (7) patients with incipient but has used large dose hormone (1 mg/kg. D) or other immunosuppressive therapy more than 1 week; (8) combined cardiovascular, cerebrovascular, endocrine and hematopoietic system, such as serious primary diseases; (9) patients of poor adherence cannot complete clinical observer; (10) during pregnancy and lactation women.

Design outcomes

Primary

Measure	Time frame
NGAL;IL-18;KIM-1;TGF-ß;	—

Countries

China

Contacts

Public ContactLiu Huafeng

the Affiliated Hospital of Guangdong Medical College

hf-liu@263.net+86 13828206812

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026